Compare Merck & Co., Inc. (MRK) vs Direxion Daily Semiconductor Bear 3X Shares (SOXS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Merck & Co., Inc. vs Direxion Daily Semiconductor Bear 3X Shares — how do they compare? Merck & Co., Inc. trades at $132.9 (market cap $321.77B), while Direxion Daily Semiconductor Bear 3X Shares trades at $40.5. The key difference: Merck & Co., Inc. pays a 2.61% dividend while Direxion Daily Semiconductor Bear 3X Shares pays none. Which is the better fit depends on your goals.
| MRK | SOXS | |
|---|---|---|
Market Cap | $321.77B | — |
Sector | Health | Leveraged / Inverse |
52-Week High | $131.84 | $1.49K |
52-Week Low | $77.60 | $32.50 |
Enterprise Value | $368.53B | — |
Dividend Yield | 2.61% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Merck (MRK) trades at $130.45, down 0.34% on the day, with a bullish technical signal from moving averages. The company reported strong earnings beats in recent quarters, with Q3 2026 results pending. Revenue reached $65.01B in 2025, and net income margin improved to 28.07%. Recent news highlights Merck's acquisition of Terns Pharmaceuticals to bolster its oncology pipeline, reflecting strategic growth initiatives amid a competitive pharmaceutical landscape.
The outlook for MRK is positive, supported by analyst consensus favoring a buy rating (67.57%) and a price target of $140.36. Key opportunities include pipeline expansion through M&A and solid cash flow generation. Risks involve high valuation multiples, such as a P/E of 104.34, and potential integration challenges from acquisitions. Investors should weigh growth prospects against elevated earnings expectations and market volatility.
SOXS, the Direxion Daily Semiconductor Bear 3X ETF, is trading at $40.97, down 9.38% today amid volatile semiconductor sector conditions. The technical picture remains bearish with moving averages signaling continued downward pressure, though oversold RSI levels suggest potential for near-term bounce. Recent news highlights SOXS benefiting from AI-fueled tech rally concerns and semiconductor stock sell-offs, with the fund executing a 1:10 stock split effective July 26, 2026.
As a leveraged inverse ETF, SOXS offers amplified exposure to semiconductor sector declines but carries significant decay and volatility risks. The fund's performance is heavily dependent on continued semiconductor weakness, which faces fundamental challenges from AI infrastructure growth and memory chip competition. Investors should understand the complex nature of inverse leveraged products before considering positions.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Merck & Co., Inc.
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent hepatitis B and pediatric diseases as well as HPV and shingles. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the firm's sales are generated in the United States.
Read more on MRK →About Direxion Daily Semiconductor Bear 3X Shares
SOXS is a leveraged ETF that seeks daily investment results corresponding to 300% of the inverse (opposite) of the daily performance of the ICE Semiconductor Index. It is designed as a tactical tool for experienced traders to take a bearish (short) position on the semiconductor sector. Due to the effects of compounding and leverage, SOXS is intended to be held for a single day and is not suitable for long-term investment.
Read more on SOXS →
